Birchview Capital, LP Albireo Pharma, Inc. Transaction History

Birchview Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$16.32 - $26.37 $65,280 - $105,480	4,000 Added 3.54%	117,000 $2.27 Million
Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $54,720 - $71,960	2,000 Added 1.8%	113,000 $3.53 Million
Q1 2021 May 14, 2021	BUY	$32.03 - $42.85 $608,570 - $814,150	19,000 Added 20.65%	111,000 $3.91 Million
Q4 2020 Feb 09, 2021	BUY	$31.56 - $42.16 $1.07 Million - $1.43 Million	34,000 Added 58.62%	92,000 $3.45 Million
Q3 2020 Nov 12, 2020	BUY	$23.19 - $41.61 $231,900 - $416,100	10,000 Added 20.83%	58,000 $1.94 Million

Q4 2019 Feb 12, 2020	BUY	$16.92 - $28.96 $169,200 - $289,600	10,000 Added 26.32%	48,000 $1.22 Million
Q2 2018 Aug 02, 2018	BUY	$28.9 - $37.31 $404,600 - $522,340	14,000 Added 58.33%	38,000 $1.35 Million
Q1 2018 May 07, 2018	BUY	$26.78 - $39.35 $642,720 - $944,400	24,000 New	24,000 $782,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Birchview Capital, LP with notifications on news.